Skip to main content

Media Category: NMO

NMOSD Panel Discussion: Pathophysiology, Monitoring, and Treatment Challenges

Written by ParadigMS Foundation on .

This expert panel discussion explores the current challenges in understanding and managing neuromyelitis optica spectrum disorder (NMOSD). Bringing together clinical perspectives, the conversation highlights gaps in pathophysiology, limitations in monitoring tools, and ongoing uncertainties in long-term treatment strategies. Despite advances in biomarkers and therapies, real-world decision-making remains largely driven by clinical experience. Key Insights from the Lecture: Antibodies alone are not sufficient to cause disease Clinical context remains essential T cells play a...

Continue reading

The clinical management of NMOSD

Written by ParadigMS Foundation on .

Neuromyelitis optica spectrum disorder (NMOSD) is a rare but severe relapsing disease of the central nervous system, characterized by attacks that lead to cumulative disability. Unlike multiple sclerosis, progression is not continuous but driven by relapses, making early diagnosis and rapid treatment essential. Advances in biomarkers, classification, and targeted therapies are reshaping how clinicians approach NMOSD management. Key Insights from the Lecture: NMOSD is a rare but globally variable disease Disability is driven by relapses, not progression Aquaporin-4 antibodies...

Continue reading

The immunopathological hallmarks of neuromyelitis optica spectrum desorder (NMOSD)

Written by ParadigMS Foundation on .

Nikolaos Grigoriadis presents a keynote lecture on the pathophysiology of Neuromyelitis Optica Spectrum Disorder (NMOSD), focusing on the immunological mechanisms underlying disease activity. The session provides clinically relevant insights into how these mechanisms translate into relapse patterns and therapeutic targets. Key Insights from the Lecture: NMOSD is a relapse-driven disease, with disability primarily resulting from acute attacks rather than progressive mechanisms Anti-aquaporin-4 antibodies are present in the majority of patients and play a central pathogenic role...

Continue reading

The Clinical Management of NMOSD in Belgium

Written by ParadigMS Foundation on .

Neuromyelitis optica spectrum disorder (NMOSD) is a rare but severe neuroinflammatory disease requiring rapid diagnosis and prompt treatment to prevent irreversible disability. In this expert-led webinar, Vincent van Pesch explores the latest advances in NMOSD diagnosis and management, with a particular focus on clinical practice in Belgium. The webinar is introduced and moderated by Melissa Cambron. The session covers diagnostic red flags, imaging features, antibody testing, and evolving therapeutic strategies that are reshaping patient care. Learning Objectives After watching...

Continue reading

Astrocytes and myelin – pathology and pathway

Written by ParadigMS Foundation on .

Advances in antibody testing and biomarker-driven diagnostics have reshaped the distinction between Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD), and MOG antibody-associated disease (MOGAD). Florian Deisenhammer reviews the historical shift from considering NMO a subtype of MS to recognizing NMOSD as a distinct antibody-mediated condition, and outlines how AQP4-IgG and MOG-IgG testing – together with characteristic MRI and CSF patterns – supports more accurate diagnosis. A central message is that these diseases can overlap clinically, but differ...

Continue reading

Astrocytes and myelin – Clinical aspects: available and future treatment

Written by ParadigMS Foundation on .

This lecture explains how antibody-mediated pathology translates into clinical phenotypes and treatment strategies in Neuromyelitis Optica Spectrum Disorder (NMOSD) and Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD). Melinda Magyari contrasts the core targets, astrocytes (aquaporin-4) in NMOSD versus myelin/oligodendrocytes (MOG) in MOGAD, and shows how these mechanisms drive differences in relapse recovery, long-term disability, and therapeutic priorities. A major emphasis is placed on early antibody testing to avoid misdiagnosis (particularly as Multiple Sclerosis) and...

Continue reading

  • 1
  • 2

FAQs

Is ParadigMS for free?

Yes, a ParadigMS subscription is free for healthcare practitioniers. 

Do subscriptions auto-renew?
Your subscription will automatically renew on yearly basis. If you cancel your plan, it will not renew at the end of your subscription cycle. 
I am a representative from industry, can I subscribe?

Free subscriptions to ParadigMS are reserved for healthcare practitioners. If you are a representative of the industry please contact us on learning@paradigms.foundation and we would advise you how to get the access to the material. 

What happens if I subscribe as a HCP if I am not?
If you subscribe as a healthcare practitioner and it is proven that you are not a healthcare practitioner, we will cancel your subscription immediately. 
I am a patient, can I subscribe?

ParadigMS is designed specifically for healthcare practitioners, with content and language tailored to their professional needs. While patients cannot subscribe directly, we encourage you to consult your healthcare provider for relevant insights and updates that may benefit you.

Why should I subscribe to ParadigMS's e-platform?

Subscribing to ParadigMS’s e-platform gives you access to up-to-date information and valuable learning materials on multiple sclerosis and NMO, along with expert insights and the latest innovations in the field. It’s an essential resource for staying informed and enhancing your knowledge in MS care.

How can I cancel my subscription?
You can cancel your subscription in your account settings. 
Can I financially support ParadigMS?

Yes, you can financially support ParadigMS! We welcome donations to help us continue our mission of advancing multiple sclerosis education and research. Your contribution directly supports the creation of educational resources, expert discussions, and innovative projects in MS care. Visit our donation page to learn more about how you can make a difference: ParadigMS Donate.